Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
Publication Date
2024
Content Type
Article
PubMed ID:
Citation
Hemasphere (2024) 8(7):e136
2024
Article
Hemasphere (2024) 8(7):e136